Niagen Bioscience (NAGE) Q2 2026 earnings review
E-Commerce Strength Masks a Rapidly Deteriorating Core
Management points to 'category leadership' and a pivot toward anti-aging pharmaceuticals, but the Q2 numbers reveal a company under severe pressure. Total revenue contracted 4% YoY to $29.8M, reversing a trend of double-digit growth seen late last year. While the direct-to-consumer e-commerce engine remains resilient (+13% YoY), cheap NMN competitors are heavily cannibalizing the Ingredient (-27% YoY) and B2B (-22% YoY) segments. More concerning: the cost of defending market share is surging. Sales & Marketing expenses spiked to 34.0% of sales (up from 26.4%), crushing operating leverage and causing Net Income to plunge 73% YoY to $1.0M.
🐂 Bull Case
Despite a flood of over 300 NMN competitors on Amazon, direct-to-consumer sales on Niagen's own website grew an impressive 23% YoY. The core premium customer base is highly sticky.
The company is officially transitioning into a multi-asset biotech. Lead therapeutic candidate NB4168 secured FDA Rare Pediatric Disease and EMA Orphan Drug designations, adding significant non-supplement upside.
🐻 Bear Case
After quarters of dismissing cheap NMN knockoffs as 'illegal' or 'ineffective,' the financial impact is now undeniable. Ingredient revenue collapsed 27%, and management officially downgraded the segment's full-year outlook.
Operating income collapsed 78% YoY to $0.7M. The company is being forced to spend heavily on marketing just to keep total revenue flat, fundamentally altering the previously attractive margin profile.
⚖️ Verdict: 🔴
Bearish. Niagen is successfully pivoting its narrative to telehealth and pharmaceuticals, but its cash-cow supplement business is struggling against aggressive, low-cost competition. Buying the stock today means betting on early-stage biotech execution rather than a high-margin supplement monopoly.
Key Themes
Customer Acquisition Costs Spiking
To combat the flood of low-cost competitors on Amazon, Niagen has opened the marketing spigot. Sales & Marketing expenses jumped 23% YoY to $10.1 million. This drove S&M to an alarming 34.0% of net sales (up from 26.4% in 25Q2). The strategy resulted in negative operating leverage: the company spent $1.9M more on marketing YoY to generate $1.3M LESS in overall revenue.
Ingredient Segment Collapses Under Competitive Pressure
The Niagen Ingredients segment, once touted as a high-growth B2B driver, fell off a cliff. Revenue dropped 27% YoY to $5.4M. Management explicitly stated that commercial partners 'continue to face a more competitive market.' This confirms our prior concerns: while Niagen's DTC brand commands loyalty, its B2B partners are bleeding market share to cheaper, non-patented NMN alternatives.
Direct-to-Consumer Platform Shows Resilience
If there is a bright spot, it is the owned E-commerce channel. While Amazon sales face severe keyword bidding pressure from NMN sellers, direct-to-consumer sales on Niagen's own website grew 23% YoY. Total E-commerce ($20.5M) now accounts for nearly 69% of total company revenue, up from 58% a year ago. The premium branding strategy works for dedicated subscribers.
Transitioning to a 'Multi-Asset Anti-Aging' Company
Management is actively shifting the corporate identity away from a dietary supplement manufacturer. The launch of the Niagen Plus telehealth platform (with LegitScript certification) introduces a recurring-revenue medical model. Furthermore, engaging Evotec for IND-enabling studies on therapeutic candidate NB4168 indicates the company is willing to absorb biotech R&D costs to chase orphan drug valuations. This fundamentally changes the company's risk/reward profile.
Other KPIs
Decelerating severely. YTD operating cash flow plummeted from $9.1 million in H1 2025 to just $1.6 million in H1 2026. While the company maintains a fortress balance sheet ($66.7M in cash, zero debt), the 'cash engine' narrative is currently broken as working capital and marketing expenses eat into cash generation.
Decelerating. Adjusted EBITDA fell sharply from $5.0 million in 25Q2 and $3.8 million sequentially in 26Q1. The margin compressed to roughly 10% from 16.2% a year prior. Shrinking B2B volumes and rising brand awareness investments are entirely responsible for the squeeze.
Guidance
Stable. The midpoint of 12.5% implies a slight deceleration from Q2's 13% growth rate. This confirms that even the healthiest segment of the business is not expected to suddenly accelerate in the back half of the year.
Reversing. In previous quarters, Niagen Ingredients was viewed as a growth engine. Management's official pivot to a negative outlook acknowledges that competitive NMN dynamics will structurally damage this segment through at least the end of 2026.
Accelerating. Management warned that 2026 is an 'important year of strategic investment.' As the company funds the Niagen Plus telehealth platform and preclinical studies for NB4168 via Evotec, investors should anticipate continued pressure on the bottom line.
Key Questions
Marketing Expense Sustainability
With Sales & Marketing surging to 34% of net sales just to maintain a flat topline, what is the current customer acquisition cost (CAC) on Amazon versus your DTC site? How high are you willing to let this ratio go to defend market share?
Ingredient Segment Contraction
You guided the ingredient business lower due to a competitive market. Are your commercial partners permanently switching to NMN formulations, and how much further do you expect this segment to contract before it finds a floor?
Biotech R&D Cash Burn
With Evotec engaged for IND-enabling studies on NB4168, how much capital is ring-fenced for pharmaceutical development in FY26 and FY27? Will this require external funding or out-licensing earlier than expected given the slowdown in cash flow from the supplement business?
Telehealth Economics
As you launch Niagen Plus at-home injection kits, how does the margin and LTV profile of a telehealth subscriber compare to your traditional e-commerce supplement customer?